JP2007505885A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007505885A5 JP2007505885A5 JP2006526717A JP2006526717A JP2007505885A5 JP 2007505885 A5 JP2007505885 A5 JP 2007505885A5 JP 2006526717 A JP2006526717 A JP 2006526717A JP 2006526717 A JP2006526717 A JP 2006526717A JP 2007505885 A5 JP2007505885 A5 JP 2007505885A5
- Authority
- JP
- Japan
- Prior art keywords
- free acid
- atorvastatin free
- crystalline form
- following
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50359203P | 2003-09-17 | 2003-09-17 | |
| PCT/IB2004/002919 WO2005026116A1 (en) | 2003-09-17 | 2004-09-06 | Crystalline forms of `r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-`(phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007505885A JP2007505885A (ja) | 2007-03-15 |
| JP2007505885A5 true JP2007505885A5 (https=) | 2007-10-25 |
Family
ID=34312443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006526717A Pending JP2007505885A (ja) | 2003-09-17 | 2004-09-06 | ［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β，δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸の結晶性形態 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20070276027A1 (https=) |
| EP (1) | EP1663969A1 (https=) |
| JP (1) | JP2007505885A (https=) |
| KR (1) | KR100781420B1 (https=) |
| CN (2) | CN101318923A (https=) |
| AR (1) | AR045654A1 (https=) |
| AU (1) | AU2004272365A1 (https=) |
| BR (1) | BRPI0414457A (https=) |
| CA (1) | CA2539158A1 (https=) |
| IL (1) | IL173651A0 (https=) |
| MX (1) | MXPA06003003A (https=) |
| NO (1) | NO20060716L (https=) |
| RU (1) | RU2315755C2 (https=) |
| TW (1) | TW200524862A (https=) |
| WO (1) | WO2005026116A1 (https=) |
| ZA (1) | ZA200602222B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8080672B2 (en) | 2005-12-13 | 2011-12-20 | Teva Pharmaceutical Industries Ltd. | Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
| MX2009011009A (es) * | 2007-04-13 | 2009-10-30 | Nicox Sa | Formas cristalinas de atorvastatin 4-(nitrooxi)butil ester. |
| WO2010080971A1 (en) * | 2009-01-12 | 2010-07-15 | Merck Sharp & Dohme Corp. | Crystalline polymorphic forms of an antidiabetic compound |
| CA3065589C (en) | 2010-06-03 | 2022-04-26 | Catalent Ontario Limited | Multi phase soft gel capsules, apparatus and method thereof |
| CA2706270C (en) * | 2010-06-03 | 2020-01-07 | Accucaps Industries Limited | Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation |
| KR20120011249A (ko) | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4681873A (en) * | 1985-07-29 | 1987-07-21 | Warner-Lambert Company | 4-amino-3-halo-2-pyridinone nucleoside and nucleotide compounds |
| US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US5003080A (en) * | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
| US5097045A (en) * | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5216174A (en) * | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5149837A (en) * | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5124482A (en) * | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
| US5245047A (en) * | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5248793A (en) * | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5103024A (en) * | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5155251A (en) * | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
| US5213995A (en) * | 1992-04-16 | 1993-05-25 | At&T Bell Laboratories | Method of making an article comprising a periodic heteroepitaxial semiconductor structure |
| JP3254219B2 (ja) * | 1993-01-19 | 2002-02-04 | ワーナー−ランバート・コンパニー | 安定な経口用のｃｉ−９８１製剤およびその製法 |
| US5298627A (en) * | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| GEP20002029B (en) * | 1995-07-17 | 2000-04-10 | Warner Lambert Company Us | (54) Crystalline [R-(R*,R*,]–2-(4-Fluorophenyl)-Beta,Delta-Dihydroxy-5-(1-Methyl-Ethyl)-3-Phenyl–4-{Phenylamino) Carbonyl} - 1H - Pyrrole - 1 - Heptanoic Acid Hemi Calcium Salt (Atorvastatin) |
| US6087511A (en) * | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
| TR199900191T2 (xx) * | 1996-07-29 | 1999-04-21 | Warner-Lambert Company | (S)-3,4-Dihidroksibutirik asitin korumal� esterlerinin sentezi i�in geli�tirilmi� proses. |
| EP1054860B1 (en) * | 1997-12-19 | 2007-04-25 | Pfizer Ireland Pharmaceuticals | Process for the synthesis of 1,3-diols |
| SI20070A (sl) | 1998-09-18 | 2000-04-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Nove soli inhibitorjev HMG-CoA reduktaze |
| PL362981A1 (en) * | 2000-11-16 | 2004-11-02 | Teva Pharmaceutical Industries Ltd. | Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide |
| US6476235B2 (en) * | 2001-01-09 | 2002-11-05 | Warner-Lambert Company | Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
-
2004
- 2004-09-06 CN CNA2008101341489A patent/CN101318923A/zh active Pending
- 2004-09-06 KR KR1020067005316A patent/KR100781420B1/ko not_active Expired - Fee Related
- 2004-09-06 CN CNA2004800269756A patent/CN1852894A/zh active Pending
- 2004-09-06 JP JP2006526717A patent/JP2007505885A/ja active Pending
- 2004-09-06 RU RU2006108385/04A patent/RU2315755C2/ru not_active IP Right Cessation
- 2004-09-06 BR BRPI0414457-0A patent/BRPI0414457A/pt not_active IP Right Cessation
- 2004-09-06 US US10/572,324 patent/US20070276027A1/en not_active Abandoned
- 2004-09-06 WO PCT/IB2004/002919 patent/WO2005026116A1/en not_active Ceased
- 2004-09-06 EP EP04769318A patent/EP1663969A1/en not_active Withdrawn
- 2004-09-06 MX MXPA06003003A patent/MXPA06003003A/es unknown
- 2004-09-06 AU AU2004272365A patent/AU2004272365A1/en not_active Abandoned
- 2004-09-06 CA CA002539158A patent/CA2539158A1/en not_active Abandoned
- 2004-09-15 TW TW093127885A patent/TW200524862A/zh unknown
- 2004-09-15 AR ARP040103296A patent/AR045654A1/es unknown
-
2006
- 2006-02-09 IL IL173651A patent/IL173651A0/en unknown
- 2006-02-14 NO NO20060716A patent/NO20060716L/no not_active Application Discontinuation
- 2006-03-16 ZA ZA200602222A patent/ZA200602222B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100431039B1 (ko) | 결정질ⅲ형[r-(r*,r*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1h-피롤-1-헵탄산헤미칼슘염(아토르바스타틴) | |
| ES2233526T3 (es) | Sal hemicalcica del acido r-(r*,r*)### -2(4-fluorofenil)-beta, delta-dihidroxi 5-(1-metiletil)-3-fenil-4 (fenilamino) carbonil 1h-pirrolo-1-heptanoico cristalina. | |
| RU2014110399A (ru) | Кристаллические формы вгс протеазного ингибитора | |
| CA2429844A1 (en) | Mch antagonists and their use in the treatment of obesity | |
| JP2012512885A5 (https=) | ||
| IL226912A (en) | The history of triazole, their preparation and their pharmaceutical preparations | |
| EP1802588A1 (en) | Substituted amino-pyrimidones and uses thereof | |
| JP2009502743A5 (https=) | ||
| JP2014524442A5 (https=) | ||
| MY141754A (en) | Selected cgrp-antagonists, process for preparing them and their use as pharmaceutical compositions | |
| CA2472954A1 (en) | Aza-arylpiperazines | |
| RS52663B2 (sr) | Nova kristalna forma tiotropijum bromida i proces njene pripreme | |
| CA2378382A1 (en) | Carboxylic acid amides, pharmaceutical compositions containing these compounds, the use and preparation thereof | |
| SI1598333T1 (sl) | Postopek za pripravo (1s)-4,5-dimetoksi-1-(metilaminometil)-benzociklobutana in njegovih adicijskih soli, kot tudi uporaba za sintezo ivabradina in njegovih adicijskih soli s farmacevtsko sprejemljivo kislino | |
| JP2011140508A (ja) | 安定なイマチニブ組成物 | |
| JP2007505885A5 (https=) | ||
| RU2001123035A (ru) | Химические соединения | |
| JP2007509143A5 (https=) | ||
| ATE444806T1 (de) | Dampfspaltungskatalysator und dessen herstellungsverfahren | |
| IL266097B (en) | Mono-orotate acid addition salt of r(–5–)–e(–2–)pyrrolidine––3ylvinyl)pyrimidine | |
| RU2005109560A (ru) | Фармацевтическая композиция, включающая кристаллический полугидрат метансульфоната сибутрамина | |
| RU2006138497A (ru) | Кристаллические формы n-десметилклозапина | |
| JP2022525102A5 (https=) | ||
| WO2007002764A3 (en) | Di-substituted oxadiazoles as cxc-chemokine receptor ligands | |
| CN107980038A (zh) | 沙库巴曲钙盐 |